The efficacy of intravitreal ranibizumab treatment in diffuse diabetic macular edema

Studies with larger number of patients and longer follow-up time is required to evaluate long term effectiveness of the treatment and factors that might affect prognosis.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Purpose: To evaluate the outcomes of intravitreal ranibizumab injection in diabetic macular edema (DME) patients, to investigate the factors that may affect the efficacy of the treatment.

📊

Key Findings & Data:The demographic characteristics, diabetes duration, antidiabetic medication, hemoglobin A1c, previous treatment for DME were recorded.

💡

Conclusion & Impact:Studies with larger number of patients and longer follow-up time is required to evaluate long term effectiveness of the treatment and factors that might affect prognosis.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the outcomes of intravitreal ranibizumab injection in diabetic macular edema (DME) patients, to investigate the factors that may affect the efficacy of the treatment. Materials and Methods: The patients with diffuse DME who were treated with intravitreal ranibizumab injection were enrolled. The demographic characteristics, diabetes duration, antidiabetic medication, hemoglobin A1c, previous treatment for DME were recorded. Diabetic retinopathy stage was evaluated on fluorescein angiography. Follow-up time and number of injections were noted. The effectiveness of the treatment was studied by comparing the best corrected visual acuity (BCVA) and central macular thickness (CMT) measured before and after the injections. The association between aforementioned factors and the change in BCVA and CMT was investigated. Results: In the study 65 eyes of 41 patients were studied. The mean follow-up time was 9.38±3 (6-18) months, the mean number of injections was 3.7±1.04 (1-6). The mean logMAR BCVA before and after the injections was 0.88±0.38 (0.1-1.8) and 0.62±0.4 (0-1.8) respectively. The mean CMT before and after the injections was 391.63±84.67 (254-733) μm and 291.89±113.65 (130-695) μm respectively. The difference in BCVA and CMT were statistically significant. There was no statistically significant correlation between the demographic, systemic, ocular factors and the difference in BCVA and CMT. Conclusion: Intravitreal injection of ranibizumab in DME is an effective treatment that provides increase in BCVA and decrease in CMT. Studies with larger number of patients and longer follow-up time is required to evaluate long term effectiveness of the treatment and factors that might affect prognosis.

Özet

Amaç: Diffüz diyabetik maküla ödemi (DMÖ) olgularında intravitreal ranibizumab enjeksiyonunun sonuçlarını değerlendirmek, tedavinin sonucunu etkileyebilecek faktörleri araştırmak. Gereç ve Yöntem: Diffüz DMÖ tanısı ile intravitreal ranibizumab enjeksiyonu uygulanan olgular çalışmaya alındı. Hastaların demografik özellikleri, diyabet süresi, kullandığı antidiyabetik ilaç, hemoglobin A1C düzeyi, daha önce DMÖ için tedavi alıp alma- dığı kaydedildi. Flöresein anjiyografide diyabetik retinopatinin evresi değerlendirildi. Takip süresi ve enjeksiyon sayısı not edildi. Olguların tedavi öncesi ve son kontroldeki en iyi düzeltilmiş görme keskinlikleri (EİDGK) ve merkezi maküla kalınlıkları (MMK) karşılaştırılarak tedavinin etkinliği incelendi. Görme keskinliği ve maküla kalınlığındaki değişimin adı geçen faktörler ile ilişkisi araştırıldı. Bulgular: Çalışmada 41 hastanın 65 gözü incelendi. Ortalama takip süresi 9.38±3 (6-18) ay, uygulanan enjeksiyon sayısı orta- lama 3.7±1.04 (1-6) idi. Tedavi öncesi ortalama EİDGK 0.88±0.38 (0.1-1.8) logMAR, son kontrolde 0.62±0.4 (0-1.8) logMAR idi. Ortalama MMK tedavi öncesi 391.63±84.67 (254-733) μm, son kontrolde 291.89±113.65 (130-695) μm bulundu. Tedavi öncesiyle son kontrol arasındaki EİDGK ve MMK farkı istatistiksel olarak anlamlıydı. Olguların demografik, sistemik, oküler özellikleri ile EİDGK ve MMKdeki değişiklik arasında istatistiksel olarak anlamlı bir ilişki saptanmadı. Sonuç: İntravitreal ranibizumab enjeksiyonu DMÖde görme keskinliğinde artış ve MMKda azalma sağlayan etkin bir tedavidir. Tedavinin geç dönem etkinliğini ve prognozda etkisi olabilecek faktörleri değerlendirebilmek için daha fazla olgunun daha uzun takiplerini içeren çalışmalara ihtiyaç vardır.

🔖

Cite This Article

ESEN, E., SIZMAZ, S., ŞİMDİVAR, G. H., ERDEM, E., YAR, K., DEMİRCAN, N. (2014). The efficacy of intravitreal ranibizumab treatment in diffuse diabetic macular edema. Retina-Vitreus, Cilt: 22 - Sayı: 4, 279–282. https://ajindex.com/articles/305023

References (10)

Bhagat N, Grigorian RA, Tutela A, et al. Diabetic macu- lar edema: pathogenesis and treatment. Surv Ophthalmol 2009;54:1-32
Lang GE. Diabetic macular edema. Ophthalmologica 2012;227:21-9
Kaynak S. Diyabetik maküler ödem ve kanıta dayalı tedavi seçenekleri. Ret-Vit 2012;20:157-75. 4.Fong AH, Lai TY. Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clin Interv Aging 2013;8:467-83. 5.Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806
Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006;113:1706-12
Nguyen QD, Shah SM, Heier JS, et al. READ-2 Study Group. Primary End Point (Six Months) Results of the ra- nibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2009;116:2175-81
Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular ede- ma. Ophthalmology 2010;117:1064-77. 9.Nguyen QD, Brown DM, Marcus DM, et al. RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801. 10.Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, mul- ticenter phase II study. Diabetes Care 2010;33:2399-405
Ünlü N, Acar MA, Üney GÖ, ve ark. Diyabetik maküla ödemi tedavisinde intravitreal ranibizumab uygulamasının görsel başarıya etkisi. Ret-Vit 2013;21:17-22
Selen F, Demirel S, Batıoğlu F,ve ark. İntravitreal ranibi- zumab enjeksiyonu uygulanan diabetik maküla ödemli olgularda görme keskinliğini etkileyen faktörler. Ret-Vit 2013;21:269-73
Bressler SB, Qin H, Beck RW,et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ra- nibizumab. Arch Ophthalmol 2012;130:1153-61
Ozturk BT, Kerimoglu H, Adam M, et al. Glucose regula- tion influences treatment outcome in ranibizumab treat- ment for diabetic macular edema. J Diabetes Complications 2011;25:298-302.